Family Dissatisfaction Greater When Intensive End-of-Life CKD Care Utilized
FRIDAY, Aug. 30, 2019 -- More intensive patterns of end-of-life care are associated with lower family ratings of quality of care among patients with advanced chronic kidney disease (CKD), according to a study published online Aug. 29 in the Clinical Journal of the American Society of Nephrology.
Claire A. Richards, Ph.D., R.N., from the Veterans Affairs Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, and colleagues designed a retrospective study among a national cohort of 9,993 veterans with advanced CKD who died between 2009 and 2015.
The researchers found that 55, 12, and 34 percent of patients did not receive dialysis, received acute dialysis, and received maintenance dialysis. More intensive patterns of end-of-life care were seen for patients treated with acute or maintenance dialysis versus those not treated with dialysis. Lower overall family ratings of end-of-life care were seen with receipt of maintenance dialysis and more intensive patterns of end-of-life care after adjustment for patient and facility characteristics, while higher overall ratings were seen in association with receipt of palliative care and hospital services. After additional adjustment for end-of-life treatment patterns, the correlation between maintenance dialysis and overall quality of care was attenuated.
"A deeper understanding of what drives both patterns and quality of end-of-life care among patients with advanced CKD may help to identify opportunities to improve care for members of this population," the authors write.
One author disclosed financial ties to the medical technology and kidney dialysis industries.
© 2020 HealthDay. All rights reserved.
Posted: August 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.